Corporate CredibilityThe market seems to be saying that MC-1 is not the block buster that has been hyped. I wonder if purchasing Aggristat was an effort to bundle a known commodity in this space with one that is novel and therapeutically suspect. I don't see the market embracing either MPH or Dr. Friesen at all at this point. There may be larger forces at work in either the corporate or scientific community that are privately detracting from MPH and creating skepticism.
At this stage, with all the advance notice of promotional seminars, presentations and "final stage" discussions, the SP ought to be hopping. It makes my decision almost one year ago to unload 1/3 at 1.65 look smarter every day. We could test one dollar the way it is going.